To investigate the contraceptive efficacy of different contraceptive ued after uterine curettage of early hydatidiform mole. Methods: The clinical data of 106 patients who had accepted curettage of early hydatidiform mole from October 2017 to April 2019 were selected as the research objects retrospectively. These patients were divided into two groups (53 cases in each group) according to different contraceptive used after uterine curettage. The patients in group A were treated with drospirenone and ethinyl estradiol tablets immediately on the day of curettage, and the patients in group B were treated with condom. The situations of blood human chorionic gonadotropin (HCG) level decreasing and menstrual recovery, and contraceptive effect of the patients in the two groups were observed. Results: The rate of the decreasing of HCG level of the patients in group B was significantly higher than that of the patients in group A, but there was no significant difference in the HCG level of the patients in the 7th week after surgery between the two groups. There were no significant differences in the rates of menstrual cycle shortening or no change, and the menstrual volume of the patients after surgery between the two groups (P＞0.05). The vaginal bleeding duration, the menstrual recovery time, the rate of prolonged menstrual cycle of the patients after surgery, and the endometrial thickness of the patients in the 3rd week after surgery in group A were significantly better than those in group B (P＜0.05). The contraceptive effective rate (92.5%) of the patients in group A was significantly higher than that (77.4%) of the patients in group B, and the incidence of complication (22.6%), such as malignant transformation, unintended pregnancy, recurrence, and arrested fetal development, of the patients was significantly lower than that (7.5%) of the patients in group B (all P＜0.05). Conclusion: The timely oral contraceptive of the patients after uterine curettage of early hydatidiform mole has reliable contraceptive effect, which can reduce their recurrence rate of hydatidiform moles, and can improve their prognostic safety.